

Umberto Gianelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8762720/publications.pdf>

Version: 2024-02-01

155
papers

4,033
citations

136885

32
h-index

138417

58
g-index

159
all docs

159
docs citations

159
times ranked

4160
citing authors

#	ARTICLE	IF	CITATIONS
1	Demystifying the diagnostic criteria of indolent systemic mastocytosis. <i>Hematological Oncology</i> , 2022, 40, 123-125.	0.8	0
2	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. <i>Thrombosis Research</i> , 2022, 210, 67-69.	0.8	3
3	Histological evaluation of ischemic alterations in donors after cardiac death: A useful tool to predict post-transplant renal function. <i>Clinical Transplantation</i> , 2022, , e14622.	0.8	4
4	Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis. <i>Cancers</i> , 2022, 14, 1799.	1.7	0
5	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
6	EAFP 2020 workshop proceedings, pediatric myeloid neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 621-646.	1.4	2
7	Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. <i>Hematological Oncology</i> , 2021, 39, 123-128.	0.8	1
8	Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019. <i>Annals of Hematology</i> , 2021, 100, 117-133.	0.8	2
9	CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents. <i>Pathobiology</i> , 2021, 88, 242-250.	1.9	0
10	Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 637116.	1.3	15
11	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. <i>Cancers</i> , 2021, 13, 4898.	1.7	8
12	Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine. <i>Journal of Clinical Medicine</i> , 2021, 10, 4809.	1.0	0
13	Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants. <i>Cancers</i> , 2021, 13, 5531.	1.7	3
14	The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. <i>Cancers</i> , 2021, 13, 5666.	1.7	11
15	Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 819097.	1.3	2
16	The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review. <i>Pathobiology</i> , 2020, 87, 2-19.	1.9	20
17	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	2.5	10
18	A woman with refractory edema and pancytopenia. <i>Internal and Emergency Medicine</i> , 2020, 16, 1267-1271.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. <i>Haematologica</i> , 2020, 105, e221-e224.	1.7	8
20	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 133-144.	0.6	52
21	Multiple adverse drug reactions during all-trans retinoic acid treatment for acute promyelocytic leukemia: differentiation syndrome, bradycardia, intestinal necrosis. , 2020, 1, 109-116.		2
22	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	2.0	18
23	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. <i>Hematological Oncology</i> , 2019, 37, 424-433.	0.8	3
24	Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies). <i>Expert Review of Hematology</i> , 2019, 12, 1077-1088.	1.0	6
25	Mitochondrial fission factor is a novel Myc-dependent regulator of mitochondrial permeability in cancer. <i>EBioMedicine</i> , 2019, 48, 353-363.	2.7	33
26	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). <i>Hematological Oncology</i> , 2019, 37, 505-507.	0.8	2
27	Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1839.	1.8	46
28	A case report of systemic mastocytosis associated with multiple hematologic non-“mast cell lineage diseases. <i>Hematological Oncology</i> , 2019, 37, 205-211.	0.8	2
29	Comments on pre-“fibrotic myelofibrosis and how should it be managed. <i>British Journal of Haematology</i> , 2019, 186, 358-360.	1.2	3
30	EDA fibronectin-“TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. <i>Journal of Experimental Medicine</i> , 2019, 216, 587-604.	4.2	36
31	Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis. <i>Internal and Emergency Medicine</i> , 2019, 14, 763-766.	1.0	0
32	Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. <i>Modern Pathology</i> , 2019, 32, 216-230.	2.9	50
33	Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2018, 93, E88-E91.	2.0	18
34	Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>European Journal of Internal Medicine</i> , 2018, 52, e25-e26.	1.0	5
35	Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review. <i>Chemotherapy</i> , 2018, 63, 340-344.	0.8	5
36	Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. <i>Annals of Hematology</i> , 2018, 97, 2117-2128.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Lymphocytic variant hypereosinophilia: a challenging diagnosis of a rare disease with pleomorphic clinical picture. <i>European Journal of Internal Medicine</i> , 2018, 57, e22-e24.	1.0	1
38	Abstract 350: Che-1/aatf-induced transcriptionally active chromatin promotes cell growth in multiple myeloma. , 2018, , .		1
39	Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome. <i>Blood</i> , 2018, 132, 1829-1829.	0.6	3
40	P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 5511-5511.	0.6	0
41	Integrating Clinical, Morphological, and Molecular Data to Assess Prognosis in Patients with Primary Myelofibrosis: A Practical Approach. <i>Blood</i> , 2018, 132, 1766-1766.	0.6	0
42	EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. <i>Blood</i> , 2018, 132, 1781-1781.	0.6	3
43	Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single center. <i>Hematological Oncology</i> , 2017, 35, 335-340.	0.8	0
44	Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version. <i>American Journal of Hematology</i> , 2017, 92, E48-E51.	2.0	21
45	Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia. <i>Histopathology</i> , 2017, 70, 1000-1008.	1.6	8
46	Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers. <i>American Journal of Hematology</i> , 2017, 92, E47-E48.	2.0	5
47	Long-Standing Isolated Autoimmune Hypothalamitis Diagnosed with Endoscopic Transventricular Biopsy. <i>World Neurosurgery</i> , 2017, 105, 1036.e5-1036.e9.	0.7	9
48	Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. <i>European Journal of Internal Medicine</i> , 2017, 43, e11-e14.	1.0	3
49	Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report. <i>Oncology Letters</i> , 2017, 13, 1307-1310.	0.8	6
50	Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. <i>American Journal of Hematology</i> , 2017, 92, E26-E29.	2.0	17
51	Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1953-1954.	0.8	7
52	An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. <i>Leukemia Research Reports</i> , 2017, 8, 7-10.	0.2	6
53	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 1062-1067.	2.0	33
54	Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. <i>Histopathology</i> , 2017, 71, 897-908.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Acute myeloid leukemia and pregnancy: clinical experience from a single center and a review of the literature. <i>BMC Cancer</i> , 2017, 17, 442.	1.1	18
56	The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. <i>Modern Pathology</i> , 2017, 30, 169-179.	2.9	18
57	Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. <i>Pathology and Oncology Research</i> , 2017, 23, 281-286.	0.9	2
58	Biological and molecular characterization of a rare case of cutaneous Richter syndrome. <i>Hematological Oncology</i> , 2017, 35, 869-874.	0.8	4
59	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	0.4	8
60	Thrombopoietin/TGF- β 1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. <i>Stem Cells</i> , 2016, 34, 1123-1133.	1.4	49
61	CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. <i>Annals of Hematology</i> , 2016, 95, 1965-1969.	0.8	7
62	Uncontrolled IL-17 Production by Intraepithelial Lymphocytes in a Case of non-IPEX Autoimmune Enteropathy. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e182.	1.3	13
63	Reply To: Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography. <i>Ultrasound Quarterly</i> , 2016, 32, 317-317.	0.3	0
64	Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2712-2715.	0.6	20
65	PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 236-241.	0.4	10
66	Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. <i>Annals of Hematology</i> , 2015, 94, 1749-1751.	0.8	7
67	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , 2015, 39, 525-529.	0.4	17
68	Neutrophilic progression in a case of polycythemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. <i>Pathology Research and Practice</i> , 2015, 211, 341-343.	1.0	5
69	Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1093-1105.	3.3	23
70	Anemia and splenomegaly: what lies behind?. <i>Internal and Emergency Medicine</i> , 2015, 10, 711-714.	1.0	0
71	Statins May Increase the Risk of Liver Dysfunction in Patients Treated With Steroids for Active Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1731-1737.	1.8	12
72	Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2015, 94, 881-882.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study. <i>European Journal of Internal Medicine</i> , 2015, 26, 611-615.	1.0	17
74	Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. <i>British Journal of Haematology</i> , 2015, 170, 890-892.	1.2	16
75	Basal Cell Carcinoma and Seborrheic Keratosis. <i>International Journal of Surgical Pathology</i> , 2015, 23, 464-464.	0.4	2
76	Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications. <i>Modern Pathology</i> , 2015, 28, 1448-1457.	2.9	23
77	Development of an algorithm for the management of cervical lymphadenopathy in children: consensus of the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Society of Pediatric Infectious Diseases and the Italian Society of Pediatric Otorhinolaryngology. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1557-1567.	2.0	31
78	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. <i>Leukemia</i> , 2015, 29, 66-75.	3.3	122
79	Insulin-like growth factor II mRNA binding protein 3 (IMP3) expression in cervical intraepithelial neoplasia and its relationship with HIV-infection status. <i>Sexual Health</i> , 2015, 12, 22.	0.4	4
80	V617F/JAK2-Positive Endothelial Cells Are Present in Bone Marrow Neovessels of Patients with Myelofibrosis and Could Derive from the Transdifferentiation of Mutated Hematopoietic Cells. <i>Blood</i> , 2015, 126, 2833-2833.	0.6	0
81	Echocardiography and Cardiopulmonary Exercise Testing for Early Detection of Pulmonary Hypertension in Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 4066-4066.	0.6	0
82	Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome. <i>Blood</i> , 2015, 126, 5281-5281.	0.6	0
83	Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Modern Pathology</i> , 2014, 27, 814-822.	2.9	48
84	Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2014, 7, 255-264.	1.0	13
85	Successful Treatment With Imatinib in a Patient With Chronic Eosinophilic Leukemia Not Otherwise Specified. <i>Journal of Clinical Oncology</i> , 2014, 32, e37-e39.	0.8	7
86	Validation of an Engineered Cell Model for In Vitro and In Vivo HIF-1 α Evaluation by Different Imaging Modalities. <i>Molecular Imaging and Biology</i> , 2014, 16, 210-223.	1.3	20
87	P.02.11 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF INFLAMMATORY CELL INFILTRATE IN ADULT-ONSET AUTOIMMUNE ENTEROPATHY AND ITS EVOLUTION WITH GLUCOCORTICOIDS. <i>Digestive and Liver Disease</i> , 2014, 46, S59.	0.4	0
88	MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. <i>Journal of Clinical Pathology</i> , 2014, 67, 697-701.	1.0	34
89	Imatinib and ruxolitinib association: first experience in two patients. <i>Haematologica</i> , 2014, 99, e76-e77.	1.7	26
90	Spleen Stiffness Measurement By Transient Elastography As a Predictor of Bone Marrow Fibrosis in Primary Myelofibrosis Patients. <i>Blood</i> , 2014, 124, 1825-1825.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. <i>Oncotarget</i> , 2014, 5, 4665-4670.	0.8	28
92	Primary Cutaneous Lymphomas. , 2014, , 173-191.		0
93	Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. <i>Modern Pathology</i> , 2013, 26, 1577-1585.	2.9	29
94	Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 219-228.	0.7	1
95	High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes. <i>American Journal of Clinical Pathology</i> , 2013, 139, 380-387.	0.4	10
96	Bone marrow localisation of metastatic melanoma and synchronous leukaemic evolution of low-risk myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2013, 66, 75-78.	1.0	4
97	The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. <i>Modern Pathology</i> , 2012, 25, 1193-1202.	2.9	99
98	An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage. <i>Leukemia and Lymphoma</i> , 2012, 53, 2296-2298.	0.6	2
99	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. <i>Haematologica</i> 2012;97(3):360-5 - Comment. <i>Haematologica</i> , 2012, 97, e5-e6.	1.7	15
100	In Vivo Imaging of Lymph Node Migration of MNP- and 111In-Labeled Dendritic Cells in a Transgenic Mouse Model of Breast Cancer (MMTV-Ras). <i>Molecular Imaging and Biology</i> , 2012, 14, 183-196.	1.3	19
101	Labeling Protocols for In Vivo Tracking of Human Skeletal Muscle Cells (HskMCs) by Magnetic Resonance and Bioluminescence Imaging. <i>Molecular Imaging and Biology</i> , 2012, 14, 47-59.	1.3	5
102	Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2011, 64, 226-231.	1.0	24
103	Severe chronic diarrhea and maculopapular rash: A case report. <i>World Journal of Gastroenterology</i> , 2011, 17, 3948.	1.4	4
104	Oxidative stress is increased in primary and post ^{tr} polycythemia vera myelofibrosis. <i>Experimental Hematology</i> , 2010, 38, 1058-1065.	0.2	39
105	Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 885-887.	0.6	11
106	Antiendothelial Cell Antibodies Induce Apoptosis of Bone Marrow Endothelial Progenitors in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2053-2063.	1.0	35
107	Clinical Relevance of Vascular Endothelial Growth Factor In Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4030-4030.	0.6	0
108	Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. <i>Leukemia</i> , 2009, 23, 2027-2033.	3.3	36

#	ARTICLE	IF	CITATIONS
109	CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. <i>Haematologica</i> , 2009, 94, 127-130.	1.7	33
110	Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical and Histopathological Implications. <i>Blood</i> , 2009, 114, 4974-4974.	0.6	0
111	Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. <i>Leukemia</i> , 2008, 22, 646-649.	3.3	47
112	The Significance of Bone Marrow Biopsy and <i>JAK2</i> ^{V617F} Mutation in the Differential Diagnosis Between the "Early" Prepolycythemic Phase of Polycythemia Vera and Essential Thrombocythemia. <i>American Journal of Clinical Pathology</i> , 2008, 130, 336-342.	0.4	62
113	Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. <i>Blood</i> , 2008, 111, 1862-1865.	0.6	78
114	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. <i>Haematologica</i> , 2007, 92, 486-492.	1.7	164
115	VEGF Expression Correlates With Microvessel Density in Philadelphia Chromosome "Negative Chronic Myeloproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2007, 128, 966-973.	0.4	48
116	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
117	Epstein-Barr Virus "Associated Nasopharyngeal Carcinoma and Local Polymorphic B-Cell Lymphoproliferative Disorder in a Patient With HIV Disease. <i>Journal of the International Association of Providers of AIDS Care</i> , 2007, 6, 255-259.	1.2	4
118	Reply. <i>Hepatology</i> , 2007, 45, 832-833.	3.6	1
119	Direct visualization of neo-vessel formation following peripheral injection of bone marrow derived CD34+ cells in experimental myocardial damage. <i>Micron</i> , 2007, 38, 321-322.	1.1	7
120	P018 Correlation between microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2007, 31, S50-S51.	0.4	0
121	Indeterminate cell histiocytosis in association with later occurrence of acute myeloblastic leukaemia. <i>British Journal of Dermatology</i> , 2007, 156, 1357-1361.	1.4	51
122	Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes. <i>Annals of Hematology</i> , 2007, 86, 185-189.	0.8	18
123	Apoptosis Taqman Low-Density Array: Analysis of Programmed Cell Death Patway in CLL. <i>Blood</i> , 2007, 110, 3369-3369.	0.6	0
124	ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 245-251.	0.6	16
125	Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. <i>Leukemia and Lymphoma</i> , 2006, 47, 1774-1781.	0.6	70
126	B-Cell Nasal Lymphoma Mimicking Hyperplastic Chronic Rhinitis. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 135, 165-167.	1.1	1

#	ARTICLE	IF	CITATIONS
127	Assessment of Selective Homing and Contribution to Vessel Formation of Cryopreserved Peripherally Injected Bone Marrow Mononuclear Cells Following Experimental Myocardial Damage. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2006, 6, 141-149.	0.2	4
128	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. <i>Histopathology</i> , 2006, 48, 529-535.	1.6	14
129	Aggressive natural killer cell leukaemia with a complex karyotype: a case report. <i>Annals of Hematology</i> , 2006, 85, 66-68.	0.8	4
130	Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. <i>Hepatology</i> , 2006, 44, 1528-1534.	3.6	249
131	Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. <i>American Journal of Hematology</i> , 2006, 81, 383-384.	2.0	3
132	Early-Polycythemia Vera (e-PV) with Thrombocytosis: Clinical Characteristics, Morphological Features and JAK2V617F Mutational Status Contributing to the Differential Diagnosis with Essential Thrombocythemia. <i>Blood</i> , 2006, 108, 3628-3628.	0.6	0
133	Immunohistochemical Expression of Vascular Endothelial Growth Factor Correlates with Microvessel Density in Philadelphia Chromosome Positive Chronic Myeloproliferative Disorders. <i>Blood</i> , 2006, 108, 2698-2698.	0.6	0
134	Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. <i>Haematologica</i> , 2006, 91, 303-10.	1.7	25
135	Fatal CD8+ Epidermotropic Cytotoxic Primary Cutaneous T-Cell Lymphoma with Multiorgan Involvement. <i>Dermatology</i> , 2005, 211, 281-285.	0.9	33
136	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1345-1351.	0.6	38
137	Nodal Peripheral T-cell Lymphoma with Secondary Granulomatous Cutaneous Involvement. <i>Acta Dermato-Venereologica</i> , 2004, 84, 325-327.	0.6	3
138	The translocation of marrow MNCs after experimental myocardial cryoinjury is proportional to the infarcted area. <i>Transfusion</i> , 2004, 44, 239-244.	0.8	4
139	Epstein-Barr Virus-Associated Lymphoma in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 425-429.	0.9	41
140	Left ventricular remodeling after experimental myocardial cryoinjury in rats. <i>Journal of Surgical Research</i> , 2004, 116, 91-97.	0.8	36
141	Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. <i>Critical Care Medicine</i> , 2004, 32, S266-S270.	0.4	54
142	Zap-70 on Bone Marrow Biopsy Is a Good Prognostic Indicator in B-CLL. <i>Blood</i> , 2004, 104, 4774-4774.	0.6	0
143	Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. <i>Haematologica</i> , 2004, 89, ECR41.	1.7	5
144	Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas. <i>Annals of Hematology</i> , 2003, 82, 691-695.	0.8	5

#	ARTICLE	IF	CITATIONS
145	Homing of peripherally injected bone marrow cells in rat after experimental myocardial injury. <i>Haematologica</i> , 2003, 88, 614-21.	1.7	18
146	Lymphomas of the Bone: A Pathological and Clinical Study of 54 Cases. <i>International Journal of Surgical Pathology</i> , 2002, 10, 257-266.	0.4	42
147	Primary intrathoracic meningioma: histopathological, immunohistochemical and ultrastructural study of two cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 196-200.	1.4	50
148	Mediastinal B-cell lymphoma: A study of its histomorphologic spectrum based on 109 cases. <i>Human Pathology</i> , 1999, 30, 178-187.	1.1	75
149	Primary Mediastinal B-Cell Lymphoma: Update of its Clinicopathologic Features. <i>Leukemia and Lymphoma</i> , 1997, 26, 115-123.	0.6	14
150	Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1646-1653.	0.8	154
151	CD56/Neural Cell Adhesion Molecule Expression in Primary Extranodal Ki-1/CD30+ Lymphoma. <i>American Journal of Dermatopathology</i> , 1997, 19, 384-390.	0.3	13
152	Morphology of Thymic Remnants Removed after Video-Assisted Thoracoscopic Extended Thymectomy in Patients with Thymomatous Myasthenia Gravis. , 1997, , 289-292.		1
153	Further Evidence Supporting the Sinus Lining Cell Nature of Splenic Littoral Cell Angiosarcoma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1531.	2.1	18
154	Littoral Cell Angiosarcoma of the Spleen Case Report with Immunohistochemical and Ultrastructural Analysis. <i>American Journal of Surgical Pathology</i> , 1995, 19, 1203-1208.	2.1	86
155	Acquired progressive lymphangioma of the skin following radiotherapy for breast carcinoma. <i>Journal of Cutaneous Pathology</i> , 1995, 22, 164-167.	0.7	58